Evidence Table 100.KQ 3—Continuous Creatinine

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome / Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD /**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lee 200836  Parallel | At high risk for CHD | Warfarin | 3.5 | Ginseng | 12 | NR  Unit: mg/dl | Mean: 0.74  SD: 0.19 | Mean:-0.04 | NR: | There were no statistically significant differences between the ginseng group and control group. | N/A |
| No Treatment | 13 | Mean:0.86  SD: 0.21 | Mean:-0.01  SD:0.8 |
| Nordøy 200054  Parallel | Mixed: Low and/or mod to high risk | Simvastatin | 20 | Omega-3 |  | NR  Unit: NR | NR | NR | NR | no significant changes were observed in serum creatinine levels | Medium |
| Placebo |  | NR | NR |
| Napoli 199852  Parallel | Unclear | Pravastatin | 20-40 | Vitamin E |  | NR  Unit: NR | NR | NR | NR | No differences in routine laboratory tests or adverse events were registered during the study (data not shown); in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups.” | Medium |
| No Treatment |  | NR | NR |
| Reyes 198459  Parallel | Mixed:  Low and/or Moderate | Hydrochlorothiazide | 50 | Magnesium | 13 | NR  Unit: NR | NR | P: NS | NR | Results state only that 'no statistically significant changes affected the electrocardiogram or the plasma variables studied during the trial'. | Medium |
| Placebo | 8 | NR | P: NS |
| Budoff 200410  Parallel | At high risk for CHD | Statins + aspirin | 10-40 | Garlic | 9 | Measured after 12 hr fast  Unit: mg/dl | NR | Mean: 0  SD: 0 | P:0.9152 | N/A | Medium |
| Placebo | 10 | NR | Mean: 0.01  SD: 0.14 |

Evidence Table 100.KQ 3—Continuous Creatinine (continued)

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome / Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD /**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Wolf 200868  Crossover | Mixed:  Low and/or Moderate | ASA | 500 | Gingko biloba |  | NR  Unit: NR | NR | NR | NR | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | Low-medium |
|  |  | NR | NR |
| De Caterina 200216  Crossover | At high risk for CHD | Simvastatin | 10-40 | Vitamin E |  | NR  Unit: pg/mg | Mean: 237  SD: 122 | NR | NR | N/A | High |
| No treatment |  | Mean: 240  SD: 124 | NR |